Key Highlights

● PDS Biotechnology rocketed with a Market Value of about $54.2 million, firmly in micro-cap territory.

● The most recent reported development was Friday's news that ImmunityBio's chairman backed a private Investment in PDS.

● No source tied Monday's move directly to the Friday PIPE report.

PDS Biotechnology rocketed during Monday's session, though no new company release was found for the day; the only recent reported development was a financing story from the previous Friday.

A rocket without a fresh release

PDS Biotechnology (NASDAQ:PDSB) rocketed on Monday, Oct. 5, ranking among the biggest gainers on intraday lists of health care movers. The company's market value was put at about $54.2 million, firmly in micro-cap territory, and the stock was one of the standout risers on the Nasdaq Composite.

No new company press release or filing dated Monday was found to explain the surge. The most recent reported development came on Friday, Oct. 2, when reports said ImmunityBio's chairman had backed a private investment in public equity, or PIPE, in PDS. No source tied Monday's move directly to that news.

ImmunityBio's own shares have also been active. They rose on Oct. 2 and climbed again in premarket trading on Monday, though no fresh company-specific news was found for ImmunityBio either.

What a PIPE is

In a PIPE, a public company sells shares or related securities directly to selected investors, usually at a negotiated price, rather than through a broad public offering. Small biotech companies often use PIPEs to raise money quickly for clinical trials. Who the investor is can matter to the market, because backing from a known industry figure can be read as a vote of confidence.

PDS Biotechnology is a clinical-stage immunotherapy company developing treatments for cancer, including candidates aimed at cancers linked to the human papillomavirus. Like most companies at that stage, it does not yet have an approved product, so its valuation rests on trial progress and its ability to fund research.

That also means the stock can be volatile. Thinly traded small companies can swing sharply when relatively few shares change hands, and big daily moves in micro-caps are common with or without a clear trigger.

Health care splits

Monday was a mixed day for health care. Large drugmakers struggled, with Merck, Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) all lower, and health care was the weakest sector at midday.

Smaller companies with news did much better. Vaxcyte (NASDAQ:PCVX) soared after its VAX-31 pneumococcal Vaccine met all primary endpoints in a pivotal trial. Genmab (NASDAQ:GMAB) jumped on Phase 3 lymphoma data with AbbVie (NYSE:ABBV).

Markets at records

The Nasdaq Composite climbed 286.45 points to a record close of 27,477.31. The S&P 500 rose 51.23 points to 7,773.95, just shy of its record, and the Dow gained 90.94 points to 51,267.90. The Russell 2000 added 14.24 points to 2,847.14.

Friday's September jobs report showed only 29,000 new payrolls, trimming bets on another Federal Reserve rate hike in October. Yet the 10-year Treasury Yield rose to its highest level since 2002, and the ISM services survey showed prices paid at the highest since July 2022.

What to watch

For PDS Biotechnology, investors will look for formal details of any financing, including its size and terms, in company announcements or regulatory filings, along with updates on its clinical programs. Its next Quarterly Report will also show its cash position.

On the broader calendar, the Federal Reserve releases minutes of its September meeting on Wednesday, Oct. 7, at 2 p.m. ET, and its next meeting runs Oct. 27–28. Earnings season begins with PepsiCo on Thursday and Delta Air Lines on Friday, followed by the big banks from Oct. 13.